Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Liangliang Dong, Dongmei Zhou, Chunxia Xin, Bing Liu & Ping Sun. (2020) MicroRNA-139 Suppresses the Tumorigenicity of Triple Negative Breast Cancer Cells by Targeting SOX8. Cancer Management and Research 12, pages 9417-9428.
Read now
Read now
Wenting Xu, Eun Ju Bae & Mi-Kyung Lee. (2018) Enhanced anticancer activity and intracellular uptake of paclitaxel-containing solid lipid nanoparticles in multidrug-resistant breast cancer cells. International Journal of Nanomedicine 13, pages 7549-7563.
Read now
Read now
Articles from other publishers (15)
Jana Raja Fischer, Hartland Warren Jackson, Natalie de Souza, Zsuzsanna Varga, Peter Schraml, Holger Moch & Bernd Bodenmiller. (2023) Multiplex imaging of breast cancer lymph node metastases identifies prognostic single-cell populations independent of clinical classifiers. Cell Reports Medicine 4:3, pages 100977.
Crossref
Crossref
Masahisa Kudo, Nicole Zalles, Rosario Distefano, Giovanni Nigita, Dario Veneziano, Pierluigi Gasparini & Carlo M. Croce. (2021) Synergistic apoptotic effect of miR-183-5p and Polo-Like kinase 1 inhibitor NMS-P937 in breast cancer cells. Cell Death & Differentiation 29:2, pages 407-419.
Crossref
Crossref
Yinxing Zhu, Yixuan Hu, Cuiju Tang, Xiaoxiang Guan & Wenwen Zhang. (2022) Platinum-based systematic therapy in triple-negative breast cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1877:1, pages 188678.
Crossref
Crossref
Yajie Ji, Siyu Li, Xinyue Zhang, Qiong Li, Qing Lu, Weili Chen, Yu Liu, Jiayu Sheng, Hongli Liang, Ke Jiang, Mengting Li, Shanyan Sha, Huangan Wu, Yan Huang & Xiaohong Xue. (2021) The Efficacy of Moxibustion for Breast Cancer Patients with Chemotherapy-Induced Myelosuppression during Adjuvant Chemotherapy: A Randomized Controlled Study. Evidence-Based Complementary and Alternative Medicine 2021, pages 1-10.
Crossref
Crossref
Mark Gray, James Meehan, Carlos Martínez-Pérez, Charlene Kay, Arran K. Turnbull, Linda R. Morrison, Lisa Y. Pang & David Argyle. (2020) Naturally-Occurring Canine Mammary Tumors as a Translational Model for Human Breast Cancer. Frontiers in Oncology 10.
Crossref
Crossref
Tarek M. A. Abdel-Fatah, Reuben J. Broom, Jun Lu, Paul M. Moseley, Baiqu Huang, Lili Li, Suling Liu, Longxin Chen, Runlin Z. Ma, Wenming Cao, Xiaojia Wang, Yan Li, Jo K. Perry, Mohammed Aleskandarany, Christopher C. Nolan, Emad A. Rakha, Peter E. Lobie, Stephen Y. T. Chan, Ian O. Ellis, Le-Ann Hwang, David P. Lane, Andrew R. Green & Dong-Xu Liu. (2019) SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment. British Journal of Cancer 120:7, pages 728-745.
Crossref
Crossref
N. I. Mekhtieva. (2019) The modern trends in diagnosis and treatment of primary operable breast cancer. Tumors of female reproductive system 14:4, pages 24-34.
Crossref
Crossref
Alma Campos-Parra, Gerardo Mitznahuatl, Abraham Pedroza-Torres, Rafael Romo, Fany Reyes, Eduardo López-Urrutia & Carlos Pérez-Plasencia. (2017) Micro-RNAs as Potential Predictors of Response to Breast Cancer Systemic Therapy: Future Clinical Implications. International Journal of Molecular Sciences 18:6, pages 1182.
Crossref
Crossref
Noa Avisar, Liat Adar, Jason Bock, Udo Müller, David Shen, Steve Barash & Laurie Pukac. (2015) First-in-human, phase I/IIa dose-escalation and safety study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy. Cancer Chemotherapy and Pharmacology 75:5, pages 929-939.
Crossref
Crossref
JIA-PENG XUE, GENG WANG, ZONG-BIN ZHAO, QUN WANG & YUN SHI. (2014) Synergistic cytotoxic effect of genistein and doxorubicin on drug-resistant human breast cancer MCF-7/Adr cells. Oncology Reports 32:4, pages 1647-1653.
Crossref
Crossref
Pierluigi Gasparini, Luciano Cascione, Matteo Fassan, Francesca Lovat, Gulnur Guler, Serdar Balci, Cigdem Irkkan, Carl Morrison, Carlo M. Croce, Charles L. Shapiro & Kay Huebner. (2014) microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. Oncotarget 5:5, pages 1174-1184.
Crossref
Crossref
A. Charehbili, D.B.Y. Fontein, J.R. Kroep, G.J. Liefers, J.S.D. Mieog, J.W.R. Nortier & C.J.H. van de Velde. (2014) Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: A systematic review. Cancer Treatment Reviews 40:1, pages 86-92.
Crossref
Crossref
Eugenia Ch Yiannakopoulou. 2014. Omics Approaches in Breast Cancer. Omics Approaches in Breast Cancer
483
498
.
Binnaz Demirkan. (2013) The Roles of Epithelial-to-Mesenchymal Transition (EMT) and Mesenchymal-to-Epithelial Transition (MET) in Breast Cancer Bone Metastasis: Potential Targets for Prevention and Treatment. Journal of Clinical Medicine 2:4, pages 264-282.
Crossref
Crossref
Daniel Hofmann, Ulrike Nitz, Oleg Gluz, Ronald E Kates, Timo Schinkoethe, Peter Staib & Nadia Harbeck. (2013) WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial. Trials 14:1, pages 261.
Crossref
Crossref